4//SEC Filing
Reardon Andrew 4
Accession 0002001011-24-000079
CIK 0000886163other
Filed
Aug 29, 8:00 PM ET
Accepted
Aug 30, 8:56 PM ET
Size
8.6 KB
Accession
0002001011-24-000079
Insider Transaction Report
Form 4
Reardon Andrew
CLO & Secretary
Transactions
- Exercise/Conversion
Common Stock
2024-08-28$52.27/sh+1,500$78,405→ 24,034 total - Sale
Common Stock
2024-08-28$106.39/sh−1,500$159,591→ 22,534 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2024-08-28−1,500→ 61,444 totalExercise: $52.27Exp: 2032-08-01→ Common Stock (1,500 underlying)
Footnotes (2)
- [F1]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $106.3200 to $106.4700. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F2]The stock option vests and is exercisable as to 12.5% of the underlying shares on February 1, 2023, and in 42 substantially equal monthly installments thereafter.
Documents
Issuer
LIGAND PHARMACEUTICALS INC
CIK 0000886163
Entity typeother
Related Parties
1- filerCIK 0001950232
Filing Metadata
- Form type
- 4
- Filed
- Aug 29, 8:00 PM ET
- Accepted
- Aug 30, 8:56 PM ET
- Size
- 8.6 KB